Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva

Analytical and Bioanalytical Chemistry

Volumn 401, Issue 3, 2011, Pages 1013-1021

  Mazzucchelli, Iolanda ^a   Rapetti, Manuela ^a   Fattore, Cinzia ^b   Franco, Valentina ^a   Gatti, Giuliana ^a   Perucca, Emilio ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

HPLC; Plasma; Rufinamide; Saliva; UV detection

Indexed keywords

AMMONIUM HYDROXIDE; ANTIEPILEPTIC DRUGS; CALIBRATION CURVES; DETECTION ASSAY; HPLC; HPLC-UV; HUMAN PLASMAS; INTERNAL STANDARDS; LIMIT OF QUANTIFICATIONS; METOCLOPRAMIDE; MOBILE PHASE; PHARMACOKINETIC STUDIES; RUFINAMIDE; SALIVA; SHIMADZU; SILICA COLUMN; THERAPEUTIC DRUG MONITORING; UV DETECTION; UV DETECTOR;

AMMONIUM COMPOUNDS; CHROMATOGRAPHY; DETECTORS; DICHLOROMETHANE; HEXANE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PATIENT MONITORING; PLASMA (HUMAN); PLASMAS; SILICA;

BODY FLUIDS;

ANTICONVULSIVE AGENT; RUFINAMIDE; TRIAZOLE DERIVATIVE;

ARTICLE; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; REPRODUCIBILITY; SALIVA; TIME; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION STUDY;

ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; MOLECULAR STRUCTURE; REPRODUCIBILITY OF RESULTS; SALIVA; SPECTROPHOTOMETRY, ULTRAVIOLET; TIME FACTORS; TRIAZOLES;

EID: 80052563086     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-011-5126-9     Document Type: Article

References (20)

1. S Arroyo 2007 Rufinamide Neurotherapeutics 4 155 162 10.1016/j.nurt.2006. 11.006 1:CAS:528:DC%2BD2sXisFaksbY%3D (Pubitemid 46107325)
2. Biton V (2009) In: Shorvon S, Perucca E, Engel J Jr (eds) The treatment of epilepsy, 3rd edn. Wiley Blackwell Publishing, Chichester
3. A Cheng-Hakimian GD Anderson JW Miller 2006 Rufinamide: pharmacology, clinical trials, and role in clinical practice Int J Clin Pract 60 1497 1501 10.1111/j.1742-1241.2006.01173.x 1:CAS:528:DC%2BD28Xhtlajt7%2FL (Pubitemid 44560351)
4. Glauser T, Bialer M (2007) In: Engel J Jr, Pedley T (eds) Epilepsy. A comprehensive textbook, 2nd edn. Lippincott Williams & Wilkins, Philadelphia
5. JW Wheless B Vazquez 2010 Rufinamide: a novel broad-spectrum antiepileptic drug Epilepsy Curr 10 1 6 10.1111/j.1535-7511.2009.01336.x
6. European Medicine Agency (EMEA) (2004) Register of designated orphan medicinal products. http://ec.europa.eu/enterprise/pharmaceuticals/register/ orphreg.htm
7. Food and Drug Administration (FDA) (2004) Cumulative list of all orphan designated products. http://www.fda.gov/orphan/designat/list.xls
8. CS Wisniewski 2010 Rufinamide: a new antiepileptic medication for the treatment of seizure associated with Lennox-Gastaut syndrome Ann Pharmacother 44 658 667 10.1345/aph.1M679 1:CAS:528:DC%2BC3cXmtlWntLs%3D
9. G Kluger T Glauser G Krauss R Seeruthun C Perdomo S Arroyo 2010 Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study Acta Neurol Scand 122 202 208 10.1111/j.1600-0404.2010.01334.x 1:STN:280:DC%2BC3cjjtlGgtw%3D%3D
10. E Perucca J Cloyd D Critchley E Fuseau 2008 Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy Epilepsia 49 1123 1141 10.1111/j.1528-1167.2008.01665.x 1:CAS:528:DC%2BD1cXpslWmtLw%3D (Pubitemid 351991401)
11. LA Brunner ML Powell 1992 An automated method for the determination of a new potential antiepileptic agent (CGP 33101) in human plasma using high performance liquid chromatography Biomed Chromatogr 6 278 282 10.1002/bmc.1130060606 1:CAS:528:DyaK3sXnt12qug%3D%3D
12. MC Rouan C Souppart L Alif D Moes JB Lecaillon J Godbillon 1995 Automated analysis of a novel anti-epileptic compound, CGP 33101, and its metabolite, CGP 47292, in body fluids by high-performance liquid chromatography and liquid-solid extraction J Chromatogr B Biomed Appl 667 307 313 10.1016/0378-4347(95)00026-F 1:CAS:528:DyaK2MXmsFGks7g%3D
13. M Contin S Mohamed C Candela F Albani R Riva A Baruzzi 2010 Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy J Chromatogr B Analyt Technol Biomed Life Sci 878 461 465 10.1016/j.jchromb.2009.11.039 1:CAS:528:DC%2BC3cXotlWiuw%3D%3D
14. G La Marca S Malvagia L Filippi M Innocenti A Rosati M Falchi S Pellacani G Moneti R Guerrini 2010 Rapid assay of rufinamide in dried blood spots by a new liquid chromatography-tandem mass spectrometric method J Pharm Biomed Anal 54 192 197 10.1016/j.jpba.2010.07.015
15. TW May R Boor B Rambeck U Jürgens E Korn-Merker C Brandt 2011 Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age and comedication Ther Drug Monit 33 214 221 1:CAS:528: DC%2BC3MXjt1Ggsb8%3D
16. Food and Drug Administration (2001) Guidance for industry: bioanalytical method validation, Rockville. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf
17. ICH Harmonized Tripartite Guideline (2005) International conference on harmonization of technical requirements for registration of pharmaceutical for human use. Validation of analytical procedures: text and methodology Q2 (R1) http://www.bioforum.org.il/Uploads/Editor/karen/q2-r1-step4.pdf
18. H Liu MR Delgado 1999 Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants Clin Pharmacokinet 36 453 470 10.2165/00003088-199936060-00006 1:CAS:528:DyaK1MXkvFeju7c%3D (Pubitemid 29317492)
19. MG Horning L Brown J Nowlin K Lertratanangkoon P Kellaway TE Zion 1977 Use of saliva in therapeutic drug monitoring Clin Chem 23 157 164 1:CAS:528:DyaE2sXhsFShsbk%3D (Pubitemid 8055738)
20. OH Drummer 2006 Drug testing in oral fluid Clin Biochem Rev 27 147 159